XPO1-mutant NSCLC without STK11/KEAP1 mutations may predict better survival to immunotherapy

Detalles Bibliográficos
Autores principales: Li, Xuanzong, Zou, Bing, Wang, Shijiang, Wang, Linlin, Yu, Jinming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8502403/
https://www.ncbi.nlm.nih.gov/pubmed/34627293
http://dx.doi.org/10.1186/s12967-021-03098-5
_version_ 1784580890019495936
author Li, Xuanzong
Zou, Bing
Wang, Shijiang
Wang, Linlin
Yu, Jinming
author_facet Li, Xuanzong
Zou, Bing
Wang, Shijiang
Wang, Linlin
Yu, Jinming
author_sort Li, Xuanzong
collection PubMed
description
format Online
Article
Text
id pubmed-8502403
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-85024032021-10-20 XPO1-mutant NSCLC without STK11/KEAP1 mutations may predict better survival to immunotherapy Li, Xuanzong Zou, Bing Wang, Shijiang Wang, Linlin Yu, Jinming J Transl Med Letter to the Editor BioMed Central 2021-10-09 /pmc/articles/PMC8502403/ /pubmed/34627293 http://dx.doi.org/10.1186/s12967-021-03098-5 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Letter to the Editor
Li, Xuanzong
Zou, Bing
Wang, Shijiang
Wang, Linlin
Yu, Jinming
XPO1-mutant NSCLC without STK11/KEAP1 mutations may predict better survival to immunotherapy
title XPO1-mutant NSCLC without STK11/KEAP1 mutations may predict better survival to immunotherapy
title_full XPO1-mutant NSCLC without STK11/KEAP1 mutations may predict better survival to immunotherapy
title_fullStr XPO1-mutant NSCLC without STK11/KEAP1 mutations may predict better survival to immunotherapy
title_full_unstemmed XPO1-mutant NSCLC without STK11/KEAP1 mutations may predict better survival to immunotherapy
title_short XPO1-mutant NSCLC without STK11/KEAP1 mutations may predict better survival to immunotherapy
title_sort xpo1-mutant nsclc without stk11/keap1 mutations may predict better survival to immunotherapy
topic Letter to the Editor
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8502403/
https://www.ncbi.nlm.nih.gov/pubmed/34627293
http://dx.doi.org/10.1186/s12967-021-03098-5
work_keys_str_mv AT lixuanzong xpo1mutantnsclcwithoutstk11keap1mutationsmaypredictbettersurvivaltoimmunotherapy
AT zoubing xpo1mutantnsclcwithoutstk11keap1mutationsmaypredictbettersurvivaltoimmunotherapy
AT wangshijiang xpo1mutantnsclcwithoutstk11keap1mutationsmaypredictbettersurvivaltoimmunotherapy
AT wanglinlin xpo1mutantnsclcwithoutstk11keap1mutationsmaypredictbettersurvivaltoimmunotherapy
AT yujinming xpo1mutantnsclcwithoutstk11keap1mutationsmaypredictbettersurvivaltoimmunotherapy

Ejemplares similares